Table 1: In Vitro Susceptibility of Aspergillus Fumigatus to Antifungal Agents 

Table 2: In Vitro Susceptibility of Aspergillus Flavus to Antifungal Agents 

Table 3: In Vitro Susceptibility of Aspergillus Terreus to Antifungal Agents 

Vignettes

Review Article: Singh, N., Treatment of opportunistic mycoses: how long is long enough ? Lancet Infect Dis 2003;3:703-08.

Review Article: Javey G, Zuravleff J.  Retinitis and Endophthalmitis. 2007.

Review Article:  Javey G, Zuravleff J.  Keratitis. 2007.

Review Article:  Efflux Pumps as a Mechanism of Antimicrobial Resistance. 2008

Review Article: Singh, N., Perfect, J. Immune Reconstitution Syndrome Associated with Opportunistic Mycoses. The LANCET Infectious Diseases 2007; Vol.7, Issue 6, 395-401.

Review Article:  Singh, N., Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses.  Eur J Clin Microbiol Infect Dis 2008;27(6):403-408.

Review Article: Wheat JL, Walsh TJ. Diagnosis of Invasive Aspergillosis by Galactomannan Antigenemia Detection Using an Enzyme Immunoassay. 2007.

Baron EJ. Mold

Baron EJ. Common Aspergillus

Guidelines: Walsh TJ, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-360.

Guideline: Guidelines for the use of antifungal agents in patients with invasive fungal infections in Taiwan. J Microbiol Immunol Infect. 2006;39:523-5.

Gubler C, Wildi SM, et al.  Disseminated Invasive Aspergillosis with Cerebral Involvement Successfully Treated with Caspofungin and Voriconazole.  Infection. 2007;35(5):364-6.

Greene RE, Schlamm HT, et al.  Imaging findings in acute invasive pulmonary aspergillosis: clinical signficance of the halo sign. Clin Infect Dis. 2007 Feb 1;44(3):373-9.

Cornely MA, Maertens J, et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44(10):1289-1297.

Walsh TJ, Raad I, et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2-12.

Raad II, Hanna HA, et al.  Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.  Leukemia 2007 Dec. 20 [Epub ahead of print].

Zaoutis T. et al. A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients. Pediatrics 2009;123:877-84.

Burgos A,  et al. Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases. Pediatrics 2008;121:e1286-e1294

Lee J. The Curse of the Mummy's Tomb and Its Link to Aspergillosis.

Lee J. Discovery of Aspergillus as a Human Pathogen.

Authors

   Nina Singh, M.D.,  David L. Paterson, M.D.